Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996002240 - USE OF INHIBITORS OF HUMAN S-CD23

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. Use of an inhibitor of the formation of human soluble CD23 (s-CD23) for the manufacture of a medicament for use in the treatment or prophylaxis of disorders in which the overproduction of S-CD23 is implicated.

2. Use according to Claim 1 , wherein the inhibitor of the formation of S-CD23 is an inhibitor of a matrix metalloprotease.

3. Use according to Claim 1 or 2, for the manufacture of a medicament for use in the treatment or prophylaxis of allergy or autoimmune disease.

4 A method for the treatment or prophylaxis of disorders in which the overproduction of S-CD23 is implicated, which method comprises the administration of an effective amount of an inhibitor of the formation of human soluble CD23 to a human or non-human mammal in need thereof.

5. A pharmaceutical composition for the treatment or prophylaxis of disorders in which the overproduction of S-CD23 is implicated, which comprises an inhibitor of the formation of human soluble CD23.

6. A pharmaceutical composition according to Claim 5, further comprising a pharmaceutically acceptable carrier.

7 A pharmaceutical composition according to Claim 5 or 6, for use in the treatment or prophylaxis of allergy or autoimmune disease.

8 A pharmaceutical compostion according to any one of Claims 5 to 7, wherein the inhibitor of the formation of S-CD23 is an inhibitor of a matrix metalloprotease.

9 Use according to any one of Claims 1 to 3, a method according to Claim 4, or a pharmaceutical compostion according to any one Claims 6 to 8, substantially as hereinbefore described with reference to the Table.

10. Use according to any one of Claims 1 to 3, a method according to Claim 4, or a pharmaceutical compostion according to any one Claims 6 to 8, substantially as hereinbefore described in any one of Preparations 1 to 9.